VSAR Stock News 27.28 05/13/2014 19:45:27 Versartis Inc. (VS

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Versartis Inc. (VSAR) 27.28 $VSAR

Growth Hormone Deficiency - Pipeline Review, H1 2014: 24 Companies and 23 Drugs Profiled
M2 - Thu May 08, 3:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdp2w7/growth_hormone) has announced the addition of the "Growth Hormone Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - Access Pharmaceuticals, Inc. - Aileron Therapeutics, Inc. - Ambrx, Inc. - Ascendis Pharma A/S - Biogenomics - Bolder Biotechnology, Inc. - Braasch Biotech LLC - CJ CheilJedang Corp. - Critical Pharmaceuticals Limited - Delpor, Inc. - Emisphere Technologies, Inc. - Flamel Technologies S.A. - HanAll Biopharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - LG Life Sciences, Ltd. - OPKO Health, Inc. - Pfenex Inc. - Phage Pharmaceuticals, Inc. - PharmaEssentia Corporation - SynBio LLC - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Versartis, Inc. - XL-protein GmbH Drug Profiles: - somatropin SR - MOD-4023 - tesamorelin acetate - MOD-4023 - ARX-201 - ACP-001 - TV-1106 - SYN-20100504RU - somatropin - HL-032 - somatropin - ALRN-5281 - somatropin biobetter - CP-016 - CobOral hGH - BBT-031 - somatropin biosimilar - IBPB-003-HH - somatropin biosimilar - Vaccine For Growth Hormone Deficiencies - xl-020 - CJ-40002 - Pegylated Growth Hormone For more information visit http://www.researchandmarkets.com/research/jd...th_hormone

Versartis Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 05, 8:42AM CDT
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced financial results for the first quarter ended March 31, 2014.

Why Versartis Inc. Shares Briefly Popped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 12:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Versartis , a wholly clinical-stage...

Versartis Announces Closing of Its Initial Public Offering and Full Exercise of Over-Allottment Option
GlobeNewswire - Wed Mar 26, 3:05PM CDT
Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company, today announced the closing of its initial public offering of 6,900,000 shares of its common stock at a public offering price of $21 per share, which included 900,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares. The shares began trading on the NASDAQ Global Select Market under the ticker symbol "VSAR" on March 21, 2014. Versartis estimates net proceeds from the offering to be approximately $132.4 million after deducting underwriting discounts and commissions and estimated offering expenses. Morgan Stanley and Citigroup acted as joint book-running managers for the offering. Cowen & Company acted as lead manager and Canaccord Genuity acted as co-manager.

Gilead Sciences Prices Hepatitis C Drug at $84,000; Versartis Commences Trading on the NASDAQ
ACCESSWIRE - Sun Mar 23, 11:30PM CDT
Oracle Corporation (NYSE: ORCL) - For an in-depth report on Oracle Corporation follow: www.BullTrends.com/stockquote/ORCL

Darden, Exelon, Nike are big market movers
AP - Fri Mar 21, 5:59PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:

5 IPOs Enjoy Solid Debuts As King Digital Looms
at Investor's Business Daily - Fri Mar 21, 3:32PM CDT
Five IPOs launched Friday, with A10 Networks (ATEN) unexpectedly opening below its pricing while Amber Road (AMBR) and Versatis (VSAR) showed the biggest pop. A10 was the largest of the deals. It priced 12.5 million shares at 15 to raise $187.5...

Versartis (VSAR) Surges on First Trading Day
at The Street - Fri Mar 21, 3:26PM CDT
Biopharmaceutical company Versartis (VSAR) closed up 47.62% to $31 on Friday, its first day of trading after the company's initial public offering. The stock surged more than 50% to a high of $36.30 for the day. Nearly 6 million shares changed hands...

Five companies make their trading debut
AP - Fri Mar 21, 11:12AM CDT
NEW YORK (AP) — Five companies ranging from a drugmaker and a financier to technology providers made their trading debuts Friday led by A10 Networks which brought in the day's top total of $187.5 million through its initial public offering.

NASDAQ Welcomes Versartis, Inc. (NASDAQ:VSAR) to The NASDAQ Stock Market
GlobeNewswire - Fri Mar 21, 11:00AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced that trading of Versartis, Inc. (Nasdaq:VSAR), a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, commenced on The NASDAQ Stock Market on March 21, 2014.

Versartis Announces Pricing of Its Initial Public Offering
GlobeNewswire - Thu Mar 20, 8:36PM CDT
Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $21 per share, before underwriting discounts and commissions. The shares are expected to begin trading on the NASDAQ Global Select Market under the ticker symbol "VSAR" on March 21, 2014. In addition, Versartis has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock from Versartis at the initial public offering price. The offering is expected to close on March 26, 2014 subject to customary closing conditions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 17

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 85

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 57

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
ROBOTERA Puts Humanoid Robots Into Logistics Night Work

Updated Category News Views 76

Midnight warehouse work is where a humanoid robot has to quit posing and earn its keep. ROBOTERA arrived at the 2026 APEC CEO Summit with a useful answer to the usual shiny-robot nonsense: it says its machines are already working in logistics centers, handling parcel induction and taking on repetitive, physically demanding shifts that people understandably do not line up...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 104

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 41

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Gildan Lawsuit Puts Revenue Quality Under a Harsh Lens

Updated Category News Views 16

Inventory can hide a multitude of sins until somebody counts the boxes, and that is the ugly question hanging over Gildan Activewear. A federal securities class action alleges the company inflated reported sales and organic-growth figures by pushing excess product into wholesaler and distributor channels. Those are allegations, not findings of fact, and investors ought to...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 70

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 9

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 111

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading

Top 5 Most Recently Viewed Articles

BMO Continues to Support United Natural Foods with Price Target

Updated Category News Views 79

BMO Capital Markets Maintains Support for United Natural Foods BMO Capital Markets has reaffirmed its position regarding United Natural Foods (NYSE: UNFI), assigning a Market Perform rating with a price target set at $23.00. This decision came after productive discussions held with UNFI's senior executives, including CEO Sandy Douglas and CFO Matteo Tarditi, focusing on...

Continue Reading
HONOR's Ambitious Shift to AI Device Ecosystem Strategy

Updated Category News Views 202

HONOR's Bold New Strategy for AI Device Ecosystem In an ambitious move, global technology brand HONOR has laid out a comprehensive strategy to transform from a traditional smartphone manufacturer into a leader in the AI device ecosystem. This announcement marks a significant pivot towards embracing advanced technologies designed to maximize human potential. The new...

Continue Reading
Roche's Strategic Move: Acquiring 89bio for Innovative Therapies

Updated Category News Views 254

Roche's Strategic Acquisition of 89bio Roche's recent decision to acquire 89bio, a clinical-stage biopharmaceutical company, highlights its commitment to enhancing treatment options for patients suffering from metabolic diseases. This acquisition centers around 89bio’s innovative therapy, pegozafermin, which is showing promise for treating moderate to severe Metabolic...

Continue Reading
Baby Safety Alliance Elevates Parent Confidence in Products

Updated Category News Views 137

Baby Safety Alliance Strengthens Trust for Parents The Baby Safety Alliance is excited to announce a significant expansion of its Verification Program. This vital initiative, previously recognized as the JPMA Certification Program, aims to simplify the process for parents seeking safe and reliable products for their babies and children. Growth of the Verification Program...

Continue Reading
Ken Kendrick: A Journey of Resilience and Recognition

Updated Category News Views 646

Ken Kendrick’s Recognition by the Horatio Alger Association Ken Kendrick, the managing general partner of the Arizona Diamondbacks, has recently been honored by the Horatio Alger Association, which has selected him for its Member Class of 2025. This prestigious recognition is awarded to individuals who have overcome personal and professional adversities, showcasing...

Continue Reading